Skip to Content
  • Previous Rank
    39
  • Revenues ($M)
    74,331
  • Revenue Percent Change
    4.2%
  • Profits ($M)
    16,323
  • Profits Percent Change
    18%
  • Market Value (as of March 31, 2015)
    279,717

Pharmaceutical sales—particularly of its new hepatitis C drug Olysio and other high margin meds—propelled the healthcare giant’s growth in 2014. The company also broadened its pipeline with the acquisitions of two biopharma firms, Alios and Covagen. Facing pricing pressure in medical devices, J&J scaled back the business, device division, dropping certain women’s health products and divesting itself of Ortho-Clinical Diagnostics. The company’s consumer segment, meanwhile, got a boost from brisk sales of painkillers and new varieties of Listerine.

Company Info

CEO
Alex Gorsky
Industry
Pharmaceuticals
Sector
Health Care
HQ Location
New Brunswick, NJ
Websitehttp://www.jnj.com
Years on List21
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)74,3314.2%
Profits ($M)16,32318%
Total Stockholder Equity69,752-
Employees126,500-
Market Value (as of March 31, 2015)279,717-

Profit Ratios

Profit as % of Revenues22%
Profits as % of Assets12.4%
Profits as % of Stockholder Equity23.4%

Earnings Per Share (last fiscal year)

Earnings Per Share ($)5.7
EPS % Change (from 2013)18.5%
EPS % Change (5 year annual rate)5.3%
EPS % Change (10 year annual rate)7.2%

Total Return

Total Return to Investors (2014)17.3%
Total Return to Investors (5 year, annualized)13.8%
Total Return to Investors (10 year, annualized)8.3%